Aktie A200230 TELCON RF PHARMACEUTICAL. INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen TELCON RF PHARMACEUTICAL. Inc.

Aktien

A200230

KR7200230001

A200230

Schlusskurs Korea S.E.
Andere Börsenplätze
 00:00:00 02.07.2024 		% 5 Tage % 1. Jan.
750 KRW +3,02 % Intraday Chart für TELCON RF PHARMACEUTICAL. Inc. -2,47 % -14,09 %
2023 TELCON RF PHARMACEUTICAL. Inc. berichtet über die Ergebnisse für das am 31. Dezember 2022 beendete Geschäftsjahr CI
2023 TELCON RF PHARMACEUTICAL. Inc. Wirtschaftsprüfer äußert Zweifel an der Unternehmensfortführung (Going Concern) CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!
100% kostenlose Registrierung
TELCON RF PHARMACEUTICAL. Inc. announced that it has received KRW 22 billion in funding from Sangsangin Savings Bank, Sangsangin Plus Savings Bank Co.,Ltd.
Abion Inc. announced that it has received KRW 19 billion in funding from TELCON RF PHARMACEUTICAL. Inc., Sangsangin Plus Savings Bank Co.,Ltd., Sangsangin Savings Bank
TELCON RF PHARMACEUTICAL. Inc. announced that it expects to receive KRW 22 billion in funding from Sangsangin Savings Bank, Sangsangin Plus Savings Bank Co.,Ltd.
Abion Inc. announced that it expects to receive KRW 19 billion in funding from TELCON RF PHARMACEUTICAL. Inc., Sangsangin Plus Savings Bank Co.,Ltd., Sangsangin Savings Bank
Abion Inc. announced that it has received KRW 7.999997049 billion in funding from TELCON RF PHARMACEUTICAL. Inc., Gencurix Inc.
TELCON RF PHARMACEUTICAL. Inc. announced that it has received KRW 6 billion in funding from Abion Inc.
TELCON RF PHARMACEUTICAL. Inc. announced that it expects to receive KRW 6 billion in funding from Abion Inc.
Abion Inc. announced that it expects to receive KRW 7.999997049 billion in funding from TELCON RF PHARMACEUTICAL. Inc., Gencurix Inc.
TELCON RF PHARMACEUTICAL. Inc.(KOSDAQ:A200230) dropped from S&P Global BMI Index
TELCON RF PHARMACEUTICAL. Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
TELCON RF PHARMACEUTICAL. Inc. Auditor Raises 'Going Concern' Doubt
KPM TECH Co., Ltd. announced that it has received KRW 9.99999925 billion in funding from TELCON RF PHARMACEUTICAL. Inc.
KPM TECH Co., Ltd. announced that it expects to receive KRW 9.99999925 billion in funding from TELCON RF PHARMACEUTICAL. Inc.
Humanigen’s Partner in South Korea Receives Ministry of Food and Drug Safety Approval to Conduct Phase 1 Study of Lenzilumab
Humanigen, Inc Announces the Execution of Licensing Agreement with Telcon Rf Pharmaceutical, Inc. and KPM Tech Co., Ltd
Telcon RF Pharmaceutical Inc. announced that it has received KRW 40.65 billion in funding from Hanil Vacuum Co., Ltd.
Telcon RF Pharmaceutical Inc. acquired an additional 9.97% stake in KPM TECH Co., Ltd. from Evercore Investment Corp. for KRW 47.9 billion.
Telcon RF Pharmaceutical Inc. announced that it has received KRW 30 billion in funding from Emmaus Life Sciences, Inc.
TELCON RF PHARMACEUTICAL. Inc. announced that it expects to receive KRW 30 billion in funding from Emmaus Life Sciences, Inc.
TELCON RF PHARMACEUTICAL. Inc. acquired an additional 3.73% stake in Abion Inc. from Leeds Investments Inc. and an individual for KRW 2.8 billion.
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A200230 Aktie
  4. Nachrichten TELCON RF PHARMACEUTICAL. Inc.
  5. Andere Sprachen